For patients with ANCA-associated vasculitis (AAV) who have kidney failure and are awaiting a kidney transplant, undergoing the transplant reduces their risk of dying by more than half compared to continuing on dialysis, a replacement therapy.

These findings, from a 20-year study of people in France with AAV listed for a kidney transplant, “underscore the importance of routinely evaluating patients with AAV with advanced chronic kidney disease for transplant eligibility as part of their standard care,” the researchers wrote.

“Notably, a considerable number of patients on the waiting list died before receiving a transplant, highlighting the need to enhance kidney transplant accessibility” for these people, they added.

Understanding ANCA-Associated Vasculitis

ANCA-associated vasculitis is a group of autoimmune disorders characterized by inflammation and damage to small blood vessels. People with AAV can develop glomerulonephritis (GN), inflammation of the kidneys’ filtering units called the glomeruli. Disease-associated GN often leads to kidney failure, known as end-stage kidney disease, which significantly impacts survival. Around 25% of patients will require kidney replacement therapy within five years of diagnosis.

Study Findings and Implications

The study, published in Kidney International Reports, analyzed outcomes among AAV patients with kidney failure who were started on dialysis and placed on a kidney transplant waiting list between 2002 and 2022. Researchers pulled patient data from a national registry of people starting on kidney replacement therapy, known as the French Renal Epidemiology and Information Network.

A total of 468 people in the registry with AAV-related end-stage kidney disease were placed on a wait list. Nearly two-thirds were males. Slightly more than half of these patients (52%) had granulomatosis with polyangiitis (GPA), while the remaining 48% had microscopic polyangiitis (MPA), the two most common types of AAV.

A total of 318 patients (68%) underwent a kidney transplant. Over a median follow-up of 61 months (about five years) since being placed on the list, nearly one-third (32%, or 148 of 468 people) died.

Researchers noted that patients who underwent a transplant were younger than those who stayed on the list over the study’s years (57 vs. 61 years old), and they had fewer comorbidities or co-existing conditions.

Causes of Death and Survival Rates

Deaths during follow-up were significantly fewer among patients who received a kidney transplant compared with those who did not (27% vs. 41%). The causes of death, either infections, cancer, or cardiovascular disease, were similar between the two groups.

More kidney transplant recipients than waiting list patients were alive five years (88% vs. 67%) and 10 years (72% vs. 28%) after placement on the list, resulting in a significantly longer median survival (13.8 vs. 5.8 years). Similar survival benefits with transplant were observed in GPA and MPA patients.

Factors associated with an increased risk of death included older age at wait list placement, having MPA, not being able to walk independently, co-existing cardiovascular conditions, and breathing problems.

Statistical analyses adjusting for these factors, as well as for sex, showed that undergoing a kidney transplant significantly associated with a 53% lower risk of death.

Recent Developments and Practical Applications

In the United States, the National Institutes of Health (NIH) and the American Society of Nephrology (ASN) have been advocating for better access to kidney transplants for patients with end-stage kidney disease. The findings from this study support their efforts, highlighting the critical need for timely consideration of kidney transplants as part of routine care for patients with AAV-ESKD.

For instance, the Mayo Clinic in Rochester, Minnesota, has implemented a comprehensive program to evaluate and prepare AAV patients for kidney transplants. This program includes early screening, pre-transplant counseling, and post-transplant support, ensuring that patients receive the best possible care.

In addition, the United Network for Organ Sharing (UNOS) has been working to streamline the organ allocation process, making it more efficient and equitable. These efforts are crucial for improving transplant accessibility and reducing wait times for patients with AAV.

Counterarguments and Future Directions

Some critics argue that the high cost of kidney transplants and the risk of complications may outweigh the benefits. However, the study’s findings clearly demonstrate that the long-term survival benefits of kidney transplants far outweigh the initial costs and risks. Moreover, advancements in transplant medicine and post-transplant care have significantly reduced complications and improved outcomes.

Future research should focus on identifying additional factors that influence transplant eligibility and outcomes, as well as developing targeted interventions to improve survival rates for AAV patients with end-stage kidney disease.

Conclusion

The study’s findings underscore the importance of kidney transplants for AAV patients with end-stage kidney disease. As the researchers noted, “In this national … study of patients with ESKD due to AAV, we found that kidney transplantation was associated with a significant survival benefit. Timely consideration of kidney transplant should be a part of routine care for patients with AAV-ESKD, and improved access to kidney transplantation for this population may considerably improve outcomes.”

For patients and healthcare providers, these findings emphasize the need for proactive evaluation and preparation for kidney transplants, ensuring that patients receive the best possible care and outcomes.